2020
Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials
Lehrer E, Kishan A, Yu J, Trifiletti D, Showalter T, Ellis R, Zaorsky N. Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials. Radiotherapy And Oncology 2020, 148: 235-242. PMID: 32505965, DOI: 10.1016/j.radonc.2020.04.037.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials, Phase III as TopicDose Fractionation, RadiationHumansMaleProspective StudiesProstatic NeoplasmsRadiation Dose HypofractionationRandomized Controlled Trials as TopicConceptsConventionally fractionated radiation therapyHypofractionated radiation therapyUltrahypofractionated radiation therapyLate grade 2Radiation therapyGrade 2Weighted random effects meta-analysesSummary effect sizesLocalized prostate cancerCompare treatment modalitiesDerSimonian and Laird methodPhase III protocolsRandom-effects meta-analysesGenitourinary toxicityEffects meta-analysesGastrointestinal toxicityProspective trialsMedian ageProstate cancerTreatment modalitiesComparing patientsIII protocolLaird methodTherapyMeta-analysis
2019
Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer
Beckta J, Nosrati J, Yu J. Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer. Urologic Oncology Seminars And Original Investigations 2019, 37: 619-627. PMID: 30738746, DOI: 10.1016/j.urolonc.2019.01.015.Peer-Reviewed Original ResearchConceptsModerate hypofractionationRadiation therapyStereotactic body radiation therapyProstate cancer radiation therapyTreatment of prostate cancerCancer radiation therapyReduced duration of treatmentDuration of treatmentStandard of careCurative intentProstate cancerHigh dosesHypofractionationReduced durationDaily sessionsFractionation schemeTherapyEffective alternativeTreatmentProstatePatientsCancerDoseMonthsCare
2017
Hypofractionated Radiotherapy for Prostate Cancer: Further Evidence to Tip the Scales
Yu J. Hypofractionated Radiotherapy for Prostate Cancer: Further Evidence to Tip the Scales. Journal Of Clinical Oncology 2017, 35: jco.2017.72.701. PMID: 28355114, DOI: 10.1200/jco.2017.72.7016.Peer-Reviewed Original Research
2016
Radiation Oncology Practice: Adjusting to a New Reimbursement Model.
Konski A, Yu J, Freedman G, Harrison L, Johnstone P. Radiation Oncology Practice: Adjusting to a New Reimbursement Model. JCO Oncology Practice 2016, 12: e576-83. PMID: 27006359, DOI: 10.1200/jop.2015.007385.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsFemaleHumansLung NeoplasmsMaleOncology Service, HospitalPalliative CareProstatic NeoplasmsRadiation Dose HypofractionationRadiation OncologyReimbursement MechanismsConceptsRelative value unitsRadiation oncologyTechnical revenueFee-for-service modelDeliver hypofractionated radiotherapyValue-based environmentRadiation oncology departmentsFee-for-serviceLung cancer casesHypofractionated radiotherapyHypofractionation usePalliative treatmentHypofractionationCancer casesPatient volumeLung cancerReimbursement modelsStaff timeOncology departmentValue unitsIncreasing skillsStaffProstateWorkforce predictionsPatients